flecainide has been researched along with Arrhythmogenic Right Ventricular Dysplasia in 7 studies
Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.
flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).
Arrhythmogenic Right Ventricular Dysplasia: A congenital cardiomyopathy that is characterized by infiltration of adipose and fibrous tissue into the RIGHT VENTRICLE wall and loss of myocardial cells. Primary injuries usually are at the free wall of right ventricular and right atria resulting in ventricular and supraventricular arrhythmias.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This is the first reported case of a young woman with a moderate to severe form of arrhythmogenic right ventricular dysplasia under flecainide treatment who, with her physician's consent, decided to have a baby." | 7.70 | Arrhythmogenic right ventricular dysplasia: pregnancy under flecainide treatment. ( Muriago, M; Nava, F; Villanova, C, 1998) |
| "This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC." | 5.72 | Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022) |
| "Recurrence was noted to occur within 2 months of therapy." | 5.46 | Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. ( Ermakov, S; Gerstenfeld, EP; Scheinman, MM; Svetlichnaya, Y, 2017) |
| "This is the first reported case of a young woman with a moderate to severe form of arrhythmogenic right ventricular dysplasia under flecainide treatment who, with her physician's consent, decided to have a baby." | 3.70 | Arrhythmogenic right ventricular dysplasia: pregnancy under flecainide treatment. ( Muriago, M; Nava, F; Villanova, C, 1998) |
| "This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC." | 1.72 | Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022) |
| "Recurrence was noted to occur within 2 months of therapy." | 1.46 | Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy. ( Ermakov, S; Gerstenfeld, EP; Scheinman, MM; Svetlichnaya, Y, 2017) |
| "Mutations in pkp2 are detected in arrhythmogenic right ventricular cardiomyopathy (ARVC)." | 1.38 | Sodium current deficit and arrhythmogenesis in a murine model of plakophilin-2 haploinsufficiency. ( Birchmeier, W; Cerrone, M; Chkourko, H; Delmar, M; Hund, T; Liang, FX; Lin, X; Mohler, P; Noorman, M; van der Nagel, R; van Rijen, HV; van Veen, TA, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Rolland, T | 1 |
| Badenco, N | 1 |
| Maupain, C | 1 |
| Duthoit, G | 1 |
| Waintraub, X | 1 |
| Laredo, M | 1 |
| Himbert, C | 1 |
| Frank, R | 1 |
| Hidden-Lucet, F | 1 |
| Gandjbakhch, E | 1 |
| Tanaka, TD | 1 |
| Suzuki, T | 1 |
| Marcus, FI | 1 |
| Ermakov, S | 2 |
| Hoffmayer, KS | 1 |
| Gerstenfeld, EP | 2 |
| Scheinman, MM | 2 |
| Svetlichnaya, Y | 1 |
| Calkins, H | 1 |
| Cerrone, M | 1 |
| Noorman, M | 1 |
| Lin, X | 1 |
| Chkourko, H | 1 |
| Liang, FX | 1 |
| van der Nagel, R | 1 |
| Hund, T | 1 |
| Birchmeier, W | 1 |
| Mohler, P | 1 |
| van Veen, TA | 1 |
| van Rijen, HV | 1 |
| Delmar, M | 1 |
| Villanova, C | 1 |
| Muriago, M | 1 |
| Nava, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Randomized Trial With Flecainide in ARVC Patients[NCT03685149] | Phase 2 | 23 participants (Actual) | Interventional | 2019-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 other studies available for flecainide and Arrhythmogenic Right Ventricular Dysplasia
| Article | Year |
|---|---|
Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy.
Topics: Arrhythmogenic Right Ventricular Dysplasia; Atrial Fibrillation; Defibrillators, Implantable; Flecai | 2022 |
Sustained Wide Complex Tachycardia in a Healthy Man.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Bisoprolol; Defibrillator | 2021 |
Combination drug therapy for patients with intractable ventricular tachycardia associated with right ventricular cardiomyopathy.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Chronic Disease; Dr | 2014 |
Use of flecainide in combination antiarrhythmic therapy in patients with arrhythmogenic right ventricular cardiomyopathy.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Catheter Ablation; Combin | 2017 |
Antiarrhythmic drug therapy in patients with arrhythmogenic dysplasia/cardiomyopathy: Is there a role for flecainide?
Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Arrhythmogenic Right Ventricular Dysplasia; Cardiomyop | 2017 |
Sodium current deficit and arrhythmogenesis in a murine model of plakophilin-2 haploinsufficiency.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Dise | 2012 |
Arrhythmogenic right ventricular dysplasia: pregnancy under flecainide treatment.
Topics: Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Female; Flecainide; Human | 1998 |